Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia

This study has been completed.
Information provided by (Responsible Party):
Fang Liu, Central South University Identifier:
First received: December 20, 2010
Last updated: December 14, 2011
Last verified: December 2011
The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.

Condition Intervention Phase
Drug: minocycline
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind,Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Schizophrenia

Resource links provided by NLM:

Further study details as provided by Central South University:

Primary Outcome Measures:
  • Mean Change from Baseline in the Composite Score From the Cognition Assessment Battery and SANS Total Scores After 16 Weeks of Treatment [ Time Frame: 16 weeks ]
    The Cognitive Assessment Battery included Making Test (TMT) ,Symbol Coding,Hopkins Verbal Learning Test-Revised ,Mazes,Brief Visuospatial Memory Test-Revised ,Continuous Performance Test-Identical Pairs,Grooved Pegboard Test,Color Trail Test,Stroop Task,Verbal Fluency,Paced Auditory Serial Addition Test and Wisconsin Card Sorting Test SANS=Scale for the Assessment of Negative Symptoms

Secondary Outcome Measures:
  • Mean Change from Baseline in the PANSS and PSP Total Scores after 16 weeks Treatment [ Time Frame: 16 weeks ]
  • Cytokine Measure [ Time Frame: 16 weeks ]
    Cytokine Measure:IL-1β,IL-6,TNF-α,Nitric Oxide (NO)、S100B

  • metabolic index [ Time Frame: 16 weeks ]
    weight,height,insulin and waist circumference,

Enrollment: 78
Study Start Date: June 2010
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: placebo
Subjects will be given with 200mg/day placebo(100mg,bid) and variable dose SGA. All drugs will be administered orally.
Drug: placebo
variable dose SGA and 100mg per capsule po(take orally) bid,16 weeks;
Active Comparator: minocycline
Subjects will be given with 200mg/day minocycline (100mg,bid)and variable dose SGA.All drugs will be administered orally.
Drug: minocycline
variable dose SGA and minocycline,100mg per capsule po(take orally) bid,16 weeks;
Other Name: Minocycline Hydrochloride Capsules

Detailed Description:
Immune-related disorders have been hypothesized as etiological factors in schizophrenia.Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile.This study was performed as a double-blind, placebocontrolled,randomized evaluation of Second generation antipsychotics(SGA) and minocycline versus SGA and placebo.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • male and female,were aged 18-40 years
  • were currently diagnosed with DSM-IV schizophrenia
  • were able to comprehend the cognition test
  • patients or guardian signed informed consent,were able to comprehend the procedure and aims of the study,agreed to join the study
  • patient's current antipsychotic medication regimen must be stable
  • must be in a stable living arrangement

Exclusion Criteria:

  • had ever been hypersensitivity to minocycline or tetracycline;
  • had acute,unstable,significant,or untreated medical illness besides schizophrenia
  • were pregnant or breast-feeding;
  • had a DSM-IV diagnosis of substance abuse or dependency;
  • had a tendency to suicide or Violence,self-harm;
  • had taken immunosuppressive agents in the preceding 3 months before study entry;
  • had influenza or fever in the preceding 2 weeks before study entry;
  • had a DSM-IV diagnosis of emotional psychosis,Mental retardation,etc.
  • has suicidal attempts or ideation or violent behavior within the last 12 months
  • patient has mental retardation or severe organic brain syndromes
  • treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01493622

China, Yunnan
Department of Psychiatry, The First Affiliated Hospital of Kunming Medical College
Kunming, Yunnan, China, 650031
Sponsors and Collaborators
Central South University
Principal Investigator: Zhao J Ping The Second Xiangya Hospital, Central South University,China
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Fang Liu, Mental Health Institute of the Second Xiangya Hospital, Central South University Identifier: NCT01493622     History of Changes
Other Study ID Numbers: CSU-2010-PSY
2010LL02 ( Other Identifier: The First Affiliated Hospital of Kunming Medical College )
Study First Received: December 20, 2010
Last Updated: December 14, 2011

Keywords provided by Central South University:
Schizophrenia minocycline cognition

Additional relevant MeSH terms:
Neurobehavioral Manifestations
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Anti-Bacterial Agents
Anti-Infective Agents processed this record on April 28, 2017